Welcome to our dedicated page for Kymera Therapeutics SEC filings (Ticker: KYMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kymera Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing oral small molecule degraders through targeted protein degradation. Its Form 8-K reports cover material events such as operating and financial results, clinical and regulatory disclosures, Regulation FD presentations, collaboration-related updates, and capital-raising arrangements involving common stock.
Proxy and governance filings describe shareholder voting matters, executive compensation, equity awards, board oversight, and bylaw provisions, including forum-selection language. The filing record also identifies KYMR common stock and recurring disclosure areas tied to the company’s pipeline, financing capacity, corporate governance, and public-company reporting obligations.
Kymera Therapeutics director John Maraganore received a grant of stock options covering 6,068 shares of common stock. The options have an exercise price of $99.87 per share and expire on June 23, 2036. All 6,068 options were reported as directly owned after the transaction. According to the footnote, these options vest in full on the earlier of June 24, 2027 or the date of Kymera’s next annual stockholder meeting.
Kymera Therapeutics director Pamela Esposito received a new stock option grant. She was granted options covering 6,068 shares of Kymera Therapeutics common stock at an exercise price of $99.87 per share, with no cash paid for the grant itself.
The option vests in full on the earlier of June 24, 2027 or the date of the company’s next annual stockholder meeting, aligning vesting with her continued board service. Following this award, Esposito holds derivative securities representing 6,068 underlying common shares according to this filing.
KYMR selling holders reported proposed sales of Common Stock on a Form 144. The filing lists multiple dispositions by Atlas Venture funds and an individual associated with the funds, with trade dates in April–June 2026.
The excerpt shows multiple transactions including large block dispositions, including Atlas Venture Fund X, L.P. (243,976 shares on 06/22/2026) and Atlas Venture Fund X, L.P. (118,178 shares on 06/24/2026). The filing identifies the sale method as Private Placement for prior issuances and cash as consideration for past sales.
KYMR files Form 144 reporting proposed sales of Common Stock by certain holders, primarily Atlas Venture funds and an individual, Bruce Booth. The excerpt lists multiple sale dates in April–June 2026 with individual transactions ranging from hundreds to hundreds of thousands of shares (examples include 243,976 shares on 06/22/2026 and 118,178 shares on 06/24/2026).
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
Kymera Therapeutics reported a routine equity compensation grant linked to Baker Bros.-affiliated funds. A single award of 6,068 non-qualified stock options exercisable into Kymera common stock was granted in connection with Felix J. Baker’s service on the board. The options have a strike price of $99.87 per share, vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, and expire on June 23, 2036. Under Baker Bros. Advisors policies, Felix Baker has no direct pecuniary interest; the economic benefit and voting and dispositive power reside with the Baker Brothers Life Sciences and 667 funds and their investment adviser.
KYMR notice reports an intended sale of 5,000 shares of Common Stock by an issuer-related source on 06/25/2026, identified as resulting from an exercise of stock options with cash as the payment method. The filing also lists multiple 10b5-1 sales by Noah Goodman totaling prior transactions on 04/09/2026, 04/10/2026, 04/14/2026, and 06/22/2026 with individual share amounts shown.
Kymera Therapeutics reported that it has completed enrollment in its global BROADEN2 Phase 2b trial of KT-621, an oral STAT6 degrader for moderate to severe atopic dermatitis. Because enrollment finished nearly six months ahead of plan, the company now expects topline Phase 2b data by year-end 2026 instead of mid-2027. Subject to regulatory discussions, Kymera plans to start Phase 3 trials in atopic dermatitis by mid-2027. KT-621 is also being studied in the BREADTH Phase 2b asthma trial, with data expected in late 2027, and previously received Fast Track designation from the FDA for atopic dermatitis and eosinophilic asthma.
KYMR reported multiple Rule 144 notices of proposed sales of Common Stock by affiliated funds and an individual associated with Atlas Venture between April and June 2026. The filings list individual transactions such as 243,976 shares on 06/22/2026 (Atlas Venture Fund X) and 100,928 shares on 06/18/2026 (Atlas Venture Fund X).
The notices present per‑transaction share counts and cash amounts for private placement resale activity and insider/affiliate dispositions; amounts are reported on specific trade dates rather than as an aggregated total.
KYMR insiders and affiliated holders submitted a Form 144 notice for proposed resales of Common Stock by selling holders, including multiple transactions by Atlas Venture funds and an individual, Bruce Booth. The excerpt lists specific sale dates, share counts, and gross proceeds for transactions in April–June 2026.
The filings show examples such as Atlas Venture Fund X, L.P. selling 243,976 shares on 06/22/2026 for $24,182,608.35 and Atlas Venture Opportunity Fund I, L.P. selling 34,152 shares on 06/22/2026 for $3,385,105.26. Multiple smaller and larger dispositions by the same holders appear across 04/15/2026 through 06/23/2026.
Kymera Therapeutics, Inc. reported the results of its Annual Meeting of Shareholders held on June 24, 2026. Shareholders elected four Class III directors — Bruce Booth, Nello Mainolfi, John Maraganore and Elena Ridloff — each to serve three-year terms ending at the 2029 annual meeting.
Shareholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 74,903,687 votes for and 2,462,732 against. In addition, shareholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 79,043,801 votes for and minimal opposition.